China
Biosimilars Market Size, Share, Trends, Forecast – 2035

The China biosimilars market was valued at USD 4.6 billion in 2025
and is projected to grow at a CAGR of 17.5% from 2026 to 2035, according to
Global Market Insights Inc. The industry is moving beyond its early focus on
recombinant proteins toward more complex monoclonal antibodies and other
biologics. Commercial growth depends not only on securing approvals but also on
translating product availability into hospital prescribing, reimbursement
access, and dependable supply. Domestic developers increasingly need strong
analytical comparability, manufacturing consistency, and pricing discipline to
compete in procurement-driven treatment channels.

Market expansion is supported by the rising chronic disease burden
across oncology, metabolic conditions, and hematology; expansion of national
volume-based procurement and reimbursement coverage; and increasing domestic
biomanufacturing capacity. Chronic diseases sustain clinical demand for
biologic therapies, while centralized procurement can make lower-priced
biosimilars available to more patients. However, tender participation also
creates margin pressure and requires manufacturers to meet delivery commitments
reliably. Investment in mammalian-cell manufacturing and process control
supports complex antibody development, although commercial success ultimately
depends on hospital formulary decisions and clinician confidence in
comparability and switching.

By product, recombinant glycosylated proteins generated USD 2,987.65
million in 2025. This category includes monoclonal antibodies used in oncology
and autoimmune treatment as well as other glycosylated biologics. The segment
benefits from substantial spending on reference biologics and institutional
treatment pathways that can direct demand toward approved alternatives. At the
same time, these products present considerable manufacturing challenges because
glycosylation and other critical quality attributes must remain consistent.
Developers with reliable mammalian-cell production, analytical
characterization, and regulatory evidence are better positioned to convert
technical approval into commercially sustainable hospital supply.

By application, hematology accounted for USD 1,454.88 million in
2025. Demand spans supportive treatment for neutropenia, anemia, and related
conditions, including patients receiving chemotherapy or managing chronic
kidney disease. Established treatment protocols can help hospitals evaluate
biosimilar alternatives when affordability and procurement availability become
important. Suppliers must still demonstrate reliable product quality,
continuity of supply, and evidence that supports prescriber confidence. These
factors make institutional relationships and reimbursement execution central to
the commercial performance of hematology-focused biosimilars.

Browse
complete summary of this research report @ https://www.gminsights.com/industry-analysis/china-biosimilars-market

Shanghai Henlius Biotech is a prominent competitor in China's
biosimilars market, with a portfolio spanning rituximab, trastuzumab,
adalimumab, bevacizumab, and pertuzumab biosimilars. The company received
Chinese regulatory approval for its pertuzumab biosimilar in May 2026. The
wider competitive landscape is shaped by molecule breadth, tender pricing,
hospital access, manufacturing reliability, and the ability to maintain supply
after procurement awards. The live report identifies Shanghai Henlius among a
group of major companies collectively accounting for approximately 58% of
market revenue in 2025, but it does not provide a separate, unambiguous
company-specific share in its detailed competitive section.

Some of the major players in this market are Bio-Thera Solutions,
Innovent Biologics, 3SBio, Qilu Pharmaceutical, Gan & Lee Pharmaceuticals,
Tonghua Dongbao Pharmaceutical, Hengrui Medicine, Hisun Pharmaceutical, Junshi
Biosciences, and Mabwell Bioscience. These participants serve different
biologic treatment areas and compete through approved portfolios, manufacturing
capabilities, distribution relationships, clinical evidence, and tender
execution. Other companies discussed in the report have distinct roles,
including commercial partnerships or innovative biologics rather than direct
approved-biosimilar competition. Market participants that balance procurement
affordability with quality systems, physician education, and pharmacovigilance
may be better positioned to build sustainable uptake.

Chapter 1   Methodology
and Scope

1.1 Market
scope and definition

1.2 Research
approach

1.3 Quality
commitments

1.3.1 GMI AI
policy and data integrity commitment

1.3.1.1 Source
consistency protocol

1.4 Research
trail and confidence scoring

1.4.1 Research
trail components

1.4.2 Scoring
components

1.5 Data
collection

1.5.1 Partial
list of primary sources

1.6 Data mining
sources

1.6.1 Paid
sources

1.7 Base
estimates and calculations

1.7.1 Revenue
share analysis

1.7.2 Base year
calculation

1.8 Forecast
model

1.9 Research
transparency addendum

1.9.1 Source
attribution framework

1.9.2 Quality
assurance metrics

1.9.3 Our
commitment to trust

Chapter 2   Executive
Summary

2.1 Industry
360° synopsis

2.2 Key market
trends

2.2.1 Business
trends

2.2.2 Product
trends

2.2.3
Application trends

2.2.4
Manufacturing type trends

2.2.5
Technology trends

2.2.6
Distribution channel trends

2.3 CXO
perspectives: Strategic imperatives

Chapter 3   Industry
Insights

3.1 Industry
ecosystem analysis

3.2 Industry
impact forces

3.2.1 Growth
drivers

3.2.1.1 Rising
chronic disease burden in China

3.2.1.2 Strong
government support & reimbursement expansion

3.2.1.3 Growing
biologics patent expirations

3.2.1.4 Rapid
expansion of domestic biomanufacturing capabilities

3.2.2 Industry
pitfalls and challenges

3.2.2.1 Complex
regulatory and approval pathways

3.2.2.2 High
development and manufacturing costs

3.2.3 Market
opportunities

3.2.3.1
Expansion into global markets (EU, Asia, emerging regions)

3.2.3.2
Advancements in AI-driven bioprocessing and manufacturing

3.2.3.3
Increasing focus on high-value monoclonal antibody biosimilars

3.3 Growth
potential analysis

3.4 Regulatory
landscape (Driven by primary research)

3.5 Technology
landscape

3.5.1 Current
technological trends

3.5.2 Emerging
technologies

3.6 Porter's
analysis

3.7 PESTEL
analysis

3.8 Impact of
AI and generative AI on the market (Driven by primary research)

3.9
Reimbursement landscape

3.10 Biosimilar
litigation landscape

3.11 Future
market trends (Driven by primary research)

3.12 Biosimilar
factor analysis

3.12.1 Access

3.12.2
Regulations

3.12.3 Payer
assessment and access

3.12.4
Physician acceptance

3.12.5 Patient
acceptance

3.13 Biosimilar
product pipeline analysis

3.14
Biosimilars approval scenario, 2022 - 2025

3.15 Biologics
patent expiry scenario

3.16
International policies on the use of biosimilar drugs

3.16.1
Interchangeability, switching and substitution

3.16.2 Supply
side policies

3.16.3
Prescribing incentives

About
Global Market Insights

Global Market Insights Inc., headquartered
in Delaware, U.S., is a global market research and consulting service provider,
offering syndicated and custom research reports along with growth consulting
services. Our business intelligence and industry research reports offer clients
penetrative insights and actionable market data specially designed and
presented to aid strategic decision making. These exhaustive reports are
designed via a proprietary research methodology and are available for key
industries such as chemicals, advanced materials, technology, renewable energy,
and biotechnology.

Contact Us

Aashit Tiwari

Corporate Sales, USA

Global Market Insights Inc.

Toll Free: +1-888-689-0688

USA: +1-302-846-7766

Europe: +44-742-759-8484

APAC: +65-3129-7718

Email: sales@gminsights.com